Table of Contents
Overview
New York, NY – Oct 08, 2025 – The Global Inhaled Nitric Oxide Market size is expected to be worth around USD 1.9 Billion by 2033 from USD 1.0 Billion in 2024, growing at a CAGR of 7.5% during the forecast period 2025 to 2033.
Inhaled Nitric Oxide (iNO) has emerged as a vital therapeutic agent in the management of severe respiratory conditions. Recognized as a selective pulmonary vasodilator, iNO plays a crucial role in improving oxygenation and reducing pulmonary hypertension without affecting systemic blood pressure. Its unique mechanism of action has established it as a critical intervention in neonatal care, cardiopulmonary surgery, and acute respiratory distress management.
The growing adoption of iNO therapy is being driven by the increasing prevalence of respiratory diseases, rising demand for advanced critical care solutions, and continuous innovation in delivery systems. It is widely used in neonatal intensive care units (NICUs) for treating hypoxic respiratory failure, significantly reducing the need for extracorporeal membrane oxygenation (ECMO). In adults, iNO has demonstrated efficacy in improving oxygenation in patients with acute respiratory distress syndrome (ARDS) and during perioperative management in high-risk cardiac procedures.
Market expansion is supported by strong clinical evidence, regulatory approvals, and ongoing research exploring its potential applications in emerging therapeutic areas. With continuous technological advancements in gas delivery devices and monitoring systems, accessibility and efficiency of treatment are expected to improve further.
The global inhaled nitric oxide market is projected to witness steady growth, reflecting its indispensable role in modern healthcare. As awareness and clinical adoption expand, iNO continues to provide life-saving benefits across diverse patient populations.
Key Takeaways
- Market Size: The inhaled nitric oxide market was valued at USD 1.0 billion in 2024 and is projected to reach approximately USD 1.9 billion by 2033.
- Market Growth: The industry is anticipated to expand at a compound annual growth rate (CAGR) of 7.5% during the forecast period from 2024 to 2033.
- Product Type Analysis: In 2023, the gas segment accounted for the largest share of the market, representing 54.7% of total revenue.
- Application Analysis: Neonatal respiratory treatment emerged as a key application area, contributing to 24.1% of the overall market share in 2023.
- End-Use Analysis: Hospitals remained the leading end-use segment, generating 60.2% of total revenue and reflecting a strong growth trajectory in 2023.
- Regional Analysis: North America dominated the global market landscape in 2023, securing the highest revenue share of 38.7%.
Regional Analysis
North America accounted for the largest revenue share of 38.7% in 2023, supported by growing clinical adoption of nitric oxide therapy in neonatal hypoxia and pulmonary hypertension. Expansion of healthcare facilities with advanced delivery capabilities has reinforced the region’s dominance.
A notable milestone was reached in January 2021, when VERO Biotech secured USD 50 million from Runway Growth Capital LLC to advance the GENOSYL Delivery System, the first FDA-approved tankless nitric oxide delivery platform. This innovation has enhanced treatment accessibility and efficiency.
Asia Pacific is projected to record the highest CAGR during the forecast period, driven by increasing healthcare investments and rising respiratory disease prevalence. India and China are at the forefront, supported by growing awareness of nitric oxide therapy’s benefits.
In January 2021, SOL expanded its presence in India’s medical gas sector by increasing its 85% stake in SICGILSOL, the country’s first provider of inhaled nitric oxide therapy. This strategic move highlights the region’s commitment to modernizing medical gas infrastructure and advancing critical care standards, thereby accelerating market growth.
Frequently Asked Questions on Inhaled Nitric Oxide
- What is inhaled nitric oxide?
Inhaled nitric oxide is a medical gas used as a selective pulmonary vasodilator. It relaxes smooth muscle in blood vessels of the lungs, improving oxygenation and reducing pulmonary hypertension in critically ill patients, especially newborns with respiratory complications. - How does inhaled nitric oxide work?
The gas diffuses rapidly into pulmonary vasculature, activating guanylate cyclase and increasing cyclic GMP levels. This leads to relaxation of vascular smooth muscle, lowering pulmonary artery pressure while avoiding systemic hypotension, making it highly targeted in therapeutic application. - What are the primary medical uses of inhaled nitric oxide?
Inhaled nitric oxide is primarily indicated for treating persistent pulmonary hypertension of the newborn (PPHN). It is also used in cases of acute respiratory distress syndrome (ARDS), post-cardiac surgery complications, and in certain off-label therapies under controlled settings. - Is inhaled nitric oxide safe for patients?
When administered under strict medical supervision, inhaled nitric oxide is generally safe. However, risks include methemoglobinemia and nitrogen dioxide toxicity if dosages exceed recommended limits. Continuous monitoring and proper equipment calibration are critical to ensure patient safety. - What are the limitations of inhaled nitric oxide therapy?
Inhaled nitric oxide provides symptomatic relief but does not cure underlying conditions. Its high cost, complex delivery systems, and need for continuous monitoring restrict widespread use, especially in low-resource healthcare settings. Long-term benefits remain limited in certain conditions. - What is driving the growth of the inhaled nitric oxide market?
The market growth is driven by increasing prevalence of respiratory disorders, rising neonatal care demand, and expanding applications in ARDS and COVID-19-related complications. Advancements in portable delivery systems are also fueling adoption across healthcare facilities worldwide. - Which regions dominate the inhaled nitric oxide market?
North America holds a dominant market share due to advanced healthcare infrastructure and high adoption of innovative therapies. Europe follows closely, while Asia-Pacific is emerging as the fastest-growing region driven by expanding neonatal care and rising healthcare investments. - Who are the major players in the inhaled nitric oxide market?
Key players include Mallinckrodt Pharmaceuticals, VERO Biotech, and Beyond Air. These companies are focusing on new product launches, regulatory approvals, and partnerships to expand their presence and strengthen their competitive position in the global inhaled nitric oxide market.
Conclusion
The inhaled nitric oxide (iNO) market is positioned for sustained growth, driven by its critical role in neonatal care, cardiopulmonary surgery, and respiratory distress management. Rising prevalence of respiratory disorders, increasing healthcare investments, and technological advancements in delivery systems are enhancing its adoption.
North America remains the dominant region, while Asia Pacific shows the fastest growth potential. Strong clinical evidence, regulatory approvals, and industry innovations, such as tankless delivery systems, are expanding accessibility and efficiency. With a projected CAGR of 7.5% and market value nearing USD 1.9 billion by 2033, iNO continues to demonstrate indispensable therapeutic and market relevance.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
